These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37352387)

  • 1. MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors.
    Kong C; Pu J; Zhao Q; Weng W; Ma L; Qian Y; Hu W; Meng X; Meng T
    Mol Cancer Ther; 2023 Oct; 22(10):1128-1143. PubMed ID: 37352387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions.
    Damelin M; Bankovich A; Bernstein J; Lucas J; Chen L; Williams S; Park A; Aguilar J; Ernstoff E; Charati M; Dushin R; Aujay M; Lee C; Ramoth H; Milton M; Hampl J; Lazetic S; Pulito V; Rosfjord E; Sun Y; King L; Barletta F; Betts A; Guffroy M; Falahatpisheh H; O'Donnell CJ; Stull R; Pysz M; Escarpe P; Liu D; Foord O; Gerber HP; Sapra P; Dylla SJ
    Sci Transl Med; 2017 Jan; 9(372):. PubMed ID: 28077676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody-Drug Conjugate for Targeting Melanoma.
    Shi J; Jiao T; Guo Q; Weng W; Ma L; Zhang Q; Wang L; Zhang J; Chen C; Huang Y; Wang M; Pan R; Tang Y; Hu W; Meng T; Liu SH; Guo J; Kong Y; Meng X
    Cancer Res; 2023 Nov; 83(22):3783-3795. PubMed ID: 37668527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer.
    Weng W; Meng T; Zhao Q; Shen Y; Fu G; Shi J; Zhang Y; Wang Z; Wang M; Pan R; Ma L; Chen C; Wang L; Zhou B; Zhang H; Pu J; Zhang J; Hu YP; Hua G; Qian Y; Liu SH; Hu W; Meng X
    Cancer Discov; 2023 Apr; 13(4):950-973. PubMed ID: 36693125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
    Maitland ML; Sachdev JC; Sharma MR; Moreno V; Boni V; Kummar S; Stringer-Reasor E; Lakhani N; Moreau AR; Xuan D; Li R; Powell EL; Jackson-Fisher A; Bowers M; Alekar S; Xin X; Tolcher AW; Calvo E
    Clin Cancer Res; 2021 Aug; 27(16):4511-4520. PubMed ID: 34083232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.
    Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
    J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
    Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
    Front Immunol; 2021; 12():665970. PubMed ID: 34475869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors.
    Weng W; Meng T; Pu J; Ma L; Shen Y; Wang Z; Pan R; Wang M; Chen C; Wang L; Zhang J; Zhou B; Shao S; Qian Y; Liu S; Hu W; Meng X
    Mol Cancer Ther; 2023 Sep; 22(9):1013-1027. PubMed ID: 37302522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers.
    Zhou W; Fang P; Yu D; Ren H; You M; Yin L; Mei F; Zhu H; Wang Z; Xu H; Cao Y; Sun X; Xu X; Bi J; Wang J; Ma L; Wang X; Chen L; Zhang Y; Cen X; Zhu X; Lou L; Liu D; Tan X; Yang J; Meng T; Shen J
    Mol Cancer Ther; 2023 Aug; 22(8):913-925. PubMed ID: 37196158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
    Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
    J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer.
    Radovich M; Solzak JP; Wang CJ; Hancock BA; Badve S; Althouse SK; Bray SM; Storniolo AMV; Ballinger TJ; Schneider BP; Miller KD
    Clin Cancer Res; 2022 Aug; 28(15):3235-3241. PubMed ID: 35551360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTK7, a Catalytically Inactive Receptor Tyrosine Kinase, Increases Oncogenic Phenotypes in Xenograft Tumors of Esophageal Squamous Cell Carcinoma KYSE-30 Cells.
    Shin WS; Park MK; Kim JH; Oh SW; Jang JY; Lee H; Lee ST
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models.
    Strop P; Tran TT; Dorywalska M; Delaria K; Dushin R; Wong OK; Ho WH; Zhou D; Wu A; Kraynov E; Aschenbrenner L; Han B; O'Donnell CJ; Pons J; Rajpal A; Shelton DL; Liu SH
    Mol Cancer Ther; 2016 Nov; 15(11):2698-2708. PubMed ID: 27582525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody Drug Conjugates in Lung Cancer.
    Merle G; Friedlaender A; Desai A; Addeo A
    Cancer J; 2022 Nov-Dec 01; 28(6):429-435. PubMed ID: 36383905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of the Promigratory and Prometastatic PTK7 Receptor Is Associated with an Adverse Clinical Outcome in Colorectal Cancer.
    Lhoumeau AC; Martinez S; Boher JM; Monges G; Castellano R; Goubard A; Doremus M; Poizat F; Lelong B; de Chaisemartin C; Bardin F; Viens P; Raoul JL; Prebet T; Aurrand-Lions M; Borg JP; Gonçalves A
    PLoS One; 2015; 10(5):e0123768. PubMed ID: 25962058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FZ-AD005, a Novel DLL3-Targeted Antibody-Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models.
    Guo Q; Gao B; Song R; Li W; Zhu S; Xie Q; Lou S; Wang L; Shen J; Zhao T; Zhang Y; Wu J; Lu W; Yang T
    Mol Cancer Ther; 2024 Oct; 23(10):1367-1377. PubMed ID: 38940283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies.
    Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR
    Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-Labeled Single-Stranded DNA Aptamer for PET Imaging of Protein Tyrosine Kinase-7 Expression.
    Jacobson O; Weiss ID; Wang L; Wang Z; Yang X; Dewhurst A; Ma Y; Zhu G; Niu G; Kiesewetter DO; Vasdev N; Liang SH; Chen X
    J Nucl Med; 2015 Nov; 56(11):1780-1785. PubMed ID: 26315836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein Tyrosine Kinase 7 (PTK7) in Breast Cancer: A Retrospective Analysis of Tumour Expression and Association with Clinical Outcome.
    Lacey K; Greener MR; Marak TR; Rakha EA; Green AR; Ellis IO; Martin SG; Storr SJ
    Cancers (Basel); 2024 Sep; 16(18):. PubMed ID: 39335176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-PTK7 Monoclonal Antibodies Exhibit Anti-Tumor Activity at the Cellular Level and in Mouse Xenograft Models of Esophageal Squamous Cell Carcinoma.
    Kim JH; Shin WS; Lee SR; Kim S; Choi SY; Lee ST
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.